WO2025157241 - USP1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/157241
Publication Date
31.07.2025
International Application No.
PCT/CN2025/074510
International Filing Date
24.01.2025
Title **
[English]
USP1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[French]
INHIBITEUR DE USP1, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
USP1抑制剂及其制备方法和用途
Applicants **
CHENGDU CHIPSCREEN PHARMACEUTICAL LTD.
Inventors
LI, Jiawen
LUO, Xinfeng
LUO, Hao
LIU, Liyang
LIU, Zhongchuan
YAO, Qifeng
XIE, Honglei
SHAN, Song
PAN, Desi
LU, Xianping
Priority Data
202410122177.2
26.01.2024
CN
202410642082.3
22.05.2024
CN
202410769430.3
14.06.2024
CN
202411448234.2
16.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3246 | |
| EPO | Filing, Examination, Granting | 21731 | |
| Japan | Filing, Examination, Granting | 2545 | |
| South Korea | Filing, Examination, Granting | 2984 | |
| USA | Filing, Examination, Granting | 8840 |
Total:
39,346
Contact Us
Abstract[English]
The present invention relates to a compound represented by formula (XI), or a pharmaceutically acceptable salt, stereoisomer, tautomer, enantiomer, diastereomer, racemate, polymorph, co-crystal, hydrate, solvate, metabolite, prodrug, and deuterated compound thereof. The present invention also relates to a pharmaceutical composition comprising the compound as an active ingredient, and a use of the compound or the pharmaceutical composition for treating and/or preventing diseases associated with USP1.[French]
La présente invention concerne un composé représenté par la formule (XI), ou un sel, un stéréoisomère, un tautomère, un énantiomère, un diastéréoisomère, un racémate, un polymorphe, un co-cristal, un hydrate, un solvate, un métabolite, un promédicament et un composé deutéré pharmaceutiquement acceptable de celui-ci. La présente invention concerne également une composition pharmaceutique comprenant le composé en tant que principe actif et une utilisation du composé ou de la composition pharmaceutique pour le traitement et/ou la prévention de maladies associées à USP1.[Chinese]
本发明涉及一种式(XI)所示化合物，或其药学上可接受的盐、立体异构体、互变异构体、对映异构体、非对映异构体、消旋体、多晶型物、共晶物、水合物、溶剂化物、代谢物、前药、氘代化合物。本发明还涉及包含所述化合物作为活性成分的药物组合物以及所述化合物或药物组合物用于治疗和/或预防与USP1相关的疾病。